CLVSQ - Clovis Oncology, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2021
31/12/2020
31/12/2019
Total revenue
133,020
148,757
164,522
143,006
Cost of revenue
36,966
38,826
41,305
34,686
Gross profit
96,054
109,931
123,217
108,320
Operating expenses
Research development
151,279
186,602
257,707
283,146
Selling general and administrative
125,528
128,400
163,894
182,769
Total operating expenses
302,742
330,222
425,405
475,626
Operating income or loss
-206,688
-220,291
-302,188
-367,306
Interest expense
34,908
31,673
23,491
16,547
Total other income/expenses net
-8,477
-10,534
-37,063
-11,915
Income before tax
-252,312
-264,928
-369,759
-398,626
Income tax expense
-406
-404
-547
1,798
Income from continuing operations
-251,906
-264,524
-369,212
-400,424
Net income
-251,906
-264,524
-369,212
-400,424
Net income available to common shareholders
-251,906
-264,524
-369,212
-400,424
Basic EPS
-
-2.29
-4.38
-7.43
Diluted EPS
-
-2.29
-4.38
-7.43
Basic average shares
-
115,528
84,307
53,873
Diluted average shares
-
115,528
84,307
53,873
EBITDA
-
-224,759
-338,070
-374,311